BioNexus Gene Lab Corp Common stock (BGLC) financials · rev $7.4M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
BioNexus Gene Lab Corp Common stock (BGLC) rev $7.4M.
| Line | FY2025 | FY2024 | Pro (2 older periods with Lician Pro) |
|---|---|---|---|
| Revenue | $7.42M | $9.51M | |
| Cost of Revenue | $6.34M | $8.22M | |
| Gross Profit | $1.09M | $1.29M | |
| Operating Income | −$2.97M | −$1.57M | |
| Net Income | −$2.98M | −$1.60M | |
| EPS (Diluted) | — | −$0.09 | |
| Unlock 5 years of statements: Lician Pro $149/yr | |||
| Line | FY2025 | FY2024 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Total Assets | $9.25M | $10.43M | |
| Current Assets | $5.45M | $7.43M | |
| Cash & Equivalents | $2.49M | $2.89M | |
| Inventory | $676.70K | $1.39M | |
| PP&E | $1.60M | $1.52M | |
| Total Liabilities | $637.86K | $2.11M | |
| Current Liabilities | $520.96K | $1.95M | |
| Shareholders' Equity | $8.61M | $8.32M | |
| Retained Earnings | −$6.43M | −$3.44M |
| Line | FY2025 | FY2024 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Operating Cash Flow | −$1.84M | −$2.23M | |
| CapEx | $36.97K | $226.99K | |
| Investing Cash Flow | $944.75K | $418.20K | |
| Financing Cash Flow | $298.84K | $144.97K | |
| Net Change in Cash | −$400.58K | −$1.63M | |
| Free Cash Flow | −$1.88M | −$2.46M |
Source: Company filings with the SEC (EDGAR) · Latest period FY2025
FAQ
What is BGLC P/E and revenue?
BioNexus Gene Lab Corp Common stock (BGLC) rev $7.4M.
What is BGLC revenue?
BioNexus Gene Lab Corp Common stock last cached revenue is $7.42M (FY2025).
Is BGLC profitable?
BioNexus Gene Lab Corp Common stock last cached net income is -$2.98M (FY2025).
What are BGLC total assets?
BioNexus Gene Lab Corp Common stock last cached total assets are $9.25M (FY2025).
What is BGLC free cash flow?
BioNexus Gene Lab Corp Common stock last cached free cash flow is -$1.88M (FY2025).
Not investment advice. Figures as reported in company filings, not a live feed.